GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Tax Provision

CAMP (Camp4 Therapeutics) Tax Provision : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Tax Provision?

Camp4 Therapeutics's tax provision for the three months ended in Sep. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.


Camp4 Therapeutics Tax Provision Historical Data

The historical data trend for Camp4 Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Tax Provision Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23
Tax Provision
- -

Camp4 Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Tax Provision Get a 7-Day Free Trial - - - - -

Camp4 Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camp4 Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Camp4 Therapeutics Headlines